FTC: Illumina/GRAIL antitrust case
Regulator
Federal Trade Commission
acted against
The FTC challenged Illumina's vertical acquisition of cancer test developer GRAIL, alleging it would let Illumina disadvantage GRAIL's rivals that depend on its sequencers.
The case
- Regulator
- Federal Trade Commission
- Docket
- 9401
- Decided
- Mar 30, 2021
- Status
- ClosedFifth Circuit upheld the FTC's liability finding in December 2023; Illumina divested GRAIL in 2024.
- Outcome
- The FTC ordered Illumina to unwind its GRAIL acquisition.
History
1 dated entryFTC: Illumina/GRAILSource
Related cases
Caption and links
In the Matter of Illumina, Inc. and GRAIL, Inc.
Also onsocials